Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR Delivered Anti-BCMA CAR-T Cells for Relapsed or Refractory Multiple Myeloma
NCT07340853Phase 1Suspended
- Start
- Feb 2026
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of UCCT-BCMA-1 in multiple myeloma (MM) (3 arms). Primary endpoints: Treatment-Emergent Adverse Events up to 12 months, Dose-Limiting Toxicity up to 30 days and 3 more. Started Feb 2026; status: suspended.
02
Drugs
UCCT-BCMA-1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07340853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340853.